Real Clinical Practice in ALK-rearranged NSCLC Patients: A Retrospective Observational Study

被引：5

作者：

Okauchi, Shinichiro ^{[1
]}

Numata, Takeshi ^{[2
,3
]}

Nawa, Takeshi ^{[4
,5
]}

Ichimura, Hideo ^{[4
,5
]}

Saito, Takefumi ^{[6
]}

Hayashihara, Kenji ^{[6
]}

Yamada, Hideyasu ^{[7
]}

Satoh, Hiroaki ^{[1
]}

Endo, Takeshi ^{[2
,3
]}

Inage, Yoshihisa ^{[2
,3
]}

Kaburagi, Takayuki ^{[8
]}

Kiyoshima, Moriyuki ^{[8
]}

Yamada, Yutaka ^{[8
]}

Tamura, Tomohiro ^{[8
]}

Saito, Kazuhito ^{[9
,10
]}

Inagaki, Masaharu ^{[9
,10
]}

Hizawa, Nobuyuki ^{[11
]}

Sato, Yukio ^{[11
]}

Shiozawa, Toshihiro ^{[11
]}

Sekine, Ikuo ^{[11
]}

Ishikawa, Hiroichi ^{[12
,13
]}

Kurihima, Koichi ^{[12
,13
]}

Sakai, Mitsuaki ^{[12
,13
]}

Kamiyama, Koichi ^{[14
]}

Kimura, Masaki ^{[14
]}

Kikuchi, Norihiro ^{[15
]}

Nakamura, Hiroyuki ^{[16
,17
]}

Furukawa, Kinya ^{[16
,17
]}

Kodama, Takahide ^{[18
]}

Miyazaki, Kunihiko ^{[18
]}

Yamashita, Takaaki ^{[19
]}

Hayashi, Shigen ^{[20
]}

Funayama, Yasunori ^{[21
]}

Nomura, Akihiro ^{[20
]}

机构：

[1] Univ Tsukuba, Mito Kyodo Gen Hosp, Mito Med Ctr, Div Resp Med, Mito, Ibaraki, Japan

[2] Mito Med Ctr, Div Resp Med, Mito, Ibaraki, Japan

[3] Mito Med Ctr, Div Thorac Surg, Mito, Ibaraki, Japan

[4] Hitachi Gen Hosp, Div Resp Med, Hitachi, Ibaraki, Japan

[5] Hitachi Gen Hosp, Div Thorac Surg, Hitachi, Ibaraki, Japan

[6] Ibarakihigashi Hosp, Div Resp Med, Tokai, Ibaraki, Japan

[7] Univ Tsukuba, Div Resp Med, Hitachinaka Med Ctr, Mito, Ibaraki, Japan

[8] Ibaraki Cent Hosp, Resp Ctr, Kasama, Ibaraki, Japan

[9] Tsuchiura Kyodo Gen Hosp, Div Resp Med, Tsuchiura, Ibaraki, Japan

[10] Tsuchiura Kyodo Gen Hosp, Div Thorac Surg, Tsuchiura, Ibaraki, Japan

[11] Univ Tsukuba, Fac Clin Med, Tsukuba, Ibaraki, Japan

[12] Tsukuba Med Ctr Hosp, Div Resp Med, Tsukuba, Ibaraki, Japan

[13] Tsukuba Med Ctr Hosp, Div Thorac Surg, Tsukuba, Ibaraki, Japan

[14] Tsukuba Kinen Hosp, Div Thorac Surg, Tsukuba, Ibaraki, Japan

[15] Kasumigaura Med Ctr, Div Resp Med, Tsuchiura, Ibaraki, Japan

[16] Tokyo Med Univ, Ibaraki Med Ctr, Div Resp Med, Ami, Ibaraki, Japan

[17] Tokyo Med Univ, Ibaraki Med Ctr, Div Thorac Surg, Ami, Ibaraki, Japan

[18] Ryugasaki Saiseikai Hosp, Div Resp Med, Ryugasaki, Japan

[19] JA Toride Med Ctr, Div Resp Med, Toride, Japan

[20] Seinan Med Ctr, Div Resp Med, Sakai, Osaka, Japan

[21] Tsukuba Gakuen Gen Hosp, Div Resp Med, Tsukuba, Ibaraki, Japan

来源：

ANTICANCER RESEARCH | 2020年 / 40卷 / 02期

关键词：

Clinical practice; alectinib; non-small cell lung cancer; anaplastic lymphoma kinase fusion gene mutation; chemotherapy; KINASE INHIBITION; TYROSINE KINASE; CRIZOTINIB; THERAPY; CHEMOTHERAPY; ALECTINIB; SURVIVAL;

D O I：

10.21873/anticanres.14029

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: To describe real clinical outcomes when using systemic therapy to treat non-small cell lung cancer (NSCLC) patients who have anaplastic lymphoma kinase (ALK) fusion gene mutation. Patients and Methods: We performed a retrospective chart review from April 2008 to March 2019 sourced from 16 medical institutes that cover a population of three million people. Results: There were 129 ALK rearranged NSCLC patients. Among them, 103 patients including 40 recurrent disease cases received ALK-tyrosine kinase inhibitors (TKI) and chemotherapy. Our treatment results were comparable to previously reported clinical trials and clinical practice studies. First-line alectinib, treatment sequence of ALK-TKI followed by another ALK-TKI, and pemetrexed-containing chemotherapy contributed to the outcome of treatment. Conclusion: By arrangement of treatment such as treatment sequence of ALK-TKI and chemotherapy regimen, it might be possible to obtain a treatment outcome almost equivalent to those of clinical trials even in real clinical practice.

引用

下载

页码：957 / 964

页数：8

共 50 条

[21] Ensartinib (X-396): what does it add for patients with ALK-rearranged NSCLC
Li, Tianhong
Ma, Weijie
Tian, Eddie C.
CHINESE CLINICAL ONCOLOGY, 2019, 8
[22] BUDGET IMPACT ANALYSIS OF ALECTINIB FOR THE TREATMENT OF PATIENTS WITH UNTREATED ALK-REARRANGED NSCLC IN ITALY
Bellone, M.
Pradelli, L.
Recchia, A.
Caputo, A.
Masetti, L.
VALUE IN HEALTH, 2018, 21 : S28 - S28
[23] ctDNA NGS for Guiding Crizotinib Treatment in ALK-Rearranged Advanced NSCLC Patients (Pts)
He, Y.
Zhao, J.
Liu, C.
Chen, R.
Xia, X.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S573 - S573
[24] Serum CEA and CYFRA Levels in ALK-rearranged NSCLC Patients: Correlation With Distant Metastasis
Numata, Takeshi
Endo, Takeo
Yanai, Hidetoshi
Ota, Kyoko
Yamamoto, Yusuke
Shimizu, Kei
Yamada, Hideyasu
Hayashihara, Kenji
Okauchi, Shinichiro
Satoh, Hiroaki
Yamada, Yutaka
Tamura, Tomohiro
Saito, Kazuto
Kikuchi, Norihiro
Kurishima, Koichi
Ishikawa, Hiroichi
Watanabe, Hiroko
Shiozawa, Toshihiro
Hizawa, Nobuyuki
Funayama, Yasunori
Hayashi, Shigen
Nakamura, Hiroyuki
Yamashita, Takaaki
IN VIVO, 2020, 34 (04): : 2095 - 2100
[25] Integrin β3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in ALK-Rearranged NSCLC
Noh, Ka-Won
Sohn, Insuk
Song, Ji-Young
Shin, Hyun-Tae
Kim, Yu-Jin
Jung, Kyungsoo
Sung, Minjung
Kim, Mingi
An, Sungbin
Han, Joungho
Lee, Se-Hoon
Lee, Mi-Sook
Choi, Yoon-La
CLINICAL CANCER RESEARCH, 2018, 24 (17) : 4162 - 4174
[26] Mechanisms of Acquired Resistance to the ALK Inhibitor Lorlatinib in ALK-Rearranged NSCLC Cell Lines
Madsen, A.
Jakobsen, K.
Demuth, C.
Sorensen, B.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2255 - S2255
[27] Clinical and molecular characteristics of ALK-rearranged Chinese lung cancer patients
Fang, Y.
Shou, J.
Han, W.
Li, H.
Zhou, X.
Li, D.
Cheng, H.
Wang, H.
Lou, F.
Cao, S.
Pan, H.
ANNALS OF ONCOLOGY, 2018, 29
[28] Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC
Blakely, Collin M.
Riess, Jonathan W.
EXPERT REVIEW OF ANTICANCER THERAPY, 2019, 19 (12) : 1061 - 1075
[29] Co-clinical quantitative tumor volume imaging in ALK-rearranged NSCLC treated with crizotinib
Nishino, Mizuki
Sacher, Adrian G.
Gandhi, Leena
Chen, Zhao
Akbay, Esra
Fedorov, Andriy
Westin, Carl F.
Hatabu, Hiroto
Johnson, Bruce E.
Hammerman, Peter
Wong, Kwok-kin
EUROPEAN JOURNAL OF RADIOLOGY, 2017, 88 : 15 - 20
[30] A Review of Clinical Outcomes of Irish Patients With ALK Rearranged NSCLC
O'Sullivan, H.
Conroy, M.
Goggin, C.
Carroll, H.
Kelly, C.
Kamel, D.
Carney, D.
Blazkova, S.
Power, D.
Higgins, M.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S666 - S666

← 1 2 3 4 5 →